The total return over the past 12 months is -82.12% vs. +16.94% for the S&P 500. So far it's up -11.08% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (82.12%) | (57.66%) | N/A | N/A | N/A | N/A |
| Total Return CAGR | (82.12%) | (57.66%) | N/A | N/A | N/A | N/A |
| Revenue CAGR | (92.30%) | N/A | +11.12% | (22.01%) | (7.27%) | +6.09% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | (484.65%) | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Neuphoria Therapeutics Inc. (NEUP)
| Year | Start price | End price | NEUP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.88 | $3.45 | (11.08%) | +14.51% | (25.59%) |
| 2025 | $3.43 | $3.88 | +13.12% | +17.72% | (4.60%) |
| 2024 | $17.76 | $3.43 | (80.69%) | +24.89% | (105.58%) |
| 2023 | $55.80 | $17.76 | (68.17%) | +26.19% | (94.36%) |
| 2022 | $150.60 | $55.80 | (62.95%) | (18.17%) | (44.78%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
